Latest market price
29.95
-0.60-1.96%
Earnings
Down 2.0% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Snapshot
| Index | — | P/E | — | EPS (ttm) | -7.01 | Insider Own | 1.73% | Shs Outstand | 59.70M | Perf Week | -18.72% |
| Market Cap | 1.79B | Forward P/E | — | EPS next Y | -3.75 | Insider Trans | -4.25% | Shs Float | 58.25M | Perf Month | -5.82% |
| Enterprise Value | 1.18B | PEG | — | EPS next Q | -1.24 | Short Float | 11.84% | Perf Quarter | -5.22% | ||
| Income | -411.00M | P/S | 18.06 | EPS this Y | — | Short Ratio | 6.22 | Perf Half Y | 8.67% | ||
| Sales | 99.00M | P/B | 1.74 | EPS next Y | — | ROA | -37.11% | Short Interest | 6.89M | Perf YTD | 10.03% |
| Book/sh | 17.19 | P/C | 2.89 | EPS next 5Y | — | ROE | -35.67% | 52W High | 46.00 -34.89% | Perf Year | -30.64% |
| Cash/sh | 10.35 | P/FCF | — | EPS past 3/5Y | — | ROIC | -43.30% | 52W Low | 22.24 34.67% | Perf 3Y | 44.20% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 56.83% — | Gross Margin | 87.92% | Volatility | 5.56% 4.60% | Perf 5Y | -38.74% |
| Dividend TTM | — | EV/Sales | 11.94 | EPS Y/Y TTM | -163.44% | Oper. Margin | -466.78% | ATR (14) | 1.92 | Perf 10Y | -39.03% |
| Dividend Ex-Date | — | Quick Ratio | 9.79 | Sales Y/Y TTM | 141.46% | Profit Margin | -418.24% | RSI (14) | 35.80 | Recom | 2.24 |
| Dividend Gr. 3/5Y | — | Current Ratio | 10.22 | EPS Q/Q | 12.44% | SMA20 | -11.46% | Beta | 0.62 | Target Price | 41.33 |
| Payout | 0.00% | Debt/Eq | 0.01 | Sales Q/Q | 275.00% | SMA50 | -10.76% | Rel Volume | 1.75 | Prev Close | 30.55 |
| Employees | 540 | LT Debt/Eq | 0.01 | Earnings | Nov 05 | SMA200 | -5.54% | Avg Volume | 1.09M | Price | 29.95 |
| IPO Date | Jul 24, 2013 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -2.13% 69.52% | Net Debt/EBITDA | — | Volume | 1,912,494 | Change | -1.96% |
Analyst Ratings
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-07-26 | Reiterated | Truist Securities | Buy | $41 → $37 |
| Jul-30-26 | Reiterated | HC Wainwright & Co. | Buy | $52 → $55 |
| Jul-21-26 | Reiterated | HC Wainwright & Co. | Buy | $54 → $52 |
| Jul-07-26 | Reiterated | Truist Securities | Buy | $36 → $41 |
| Jul-07-26 | Reiterated | RBC Capital | Sector Perform | $53 → $32 |
| Jun-15-26 | Reiterated | HC Wainwright & Co. | Buy | $50 → $54 |
| Apr-30-26 | Reiterated | Truist Securities | Buy | $39 → $36 |
| Apr-20-26 | Reiterated | HC Wainwright & Co. | Buy | $62 → $50 |
| Feb-12-26 | Reiterated | Truist Financial | Buy | $38 → $39 |
| Dec-26-25 | Reiterated | Leerink Partners | Outperform | $34 → $40 |
Latest News· Times ET
Oct-30-26
Oct-30-2602:27PM
07:00AM
Oct-29-26
Oct-29-2611:06AM
05:16AM
Oct-20-26
Oct-20-2607:23PM
Oct-14-26
Oct-08-26
Oct-08-2607:00AM
Oct-07-26
Oct-07-2607:04AM
Oct-06-26
Oct-02-26
Sep-29-26
Sep-21-26
Sep-21-2609:40AM
Sep-10-26
Sep-10-2604:02AM
Sep-04-26
Sep-04-2611:30AM
03:26AM
Company
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
Ownership
Per-holder 13F data hasn't been ingested for this ticker yet.
Financial Statements
DataTimeframe
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 99 | 54 | 36 | 27 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 12 | 12 | 4 | 10 | — | — | — | — | — | |
| Gross Profit | 87 | 43 | 32 | 17 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 193 | 180 | 157 | 120 | — | — | — | — | — | |
| Research and Development | 353 | 334 | 301 | 289 | — | — | — | — | — | |
| Other Operating Expense | -1 | 1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -460 | -472 | -426 | -391 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 47 | 58 | 1,144 | 39 | — | — | — | — | — | |
| Net Income Before Taxes | -412 | -414 | 718 | -352 | — | — | — | — | — | |
| Income Taxes | -1 | -1 | 44 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -411 | -413 | 674 | -352 | — | — | — | — | — | |
| Net Income From Continuing Operations | -411 | -413 | 674 | -352 | — | — | — | — | — | |
| Net Income | -411 | -413 | 674 | -352 | — | — | — | — | — | |
| EPS (Recurring) | -7.01 | -7.12 | 11.86 | -6.33 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -7.01 | -7.12 | 11.86 | -6.33 | — | — | — | — | — | |
| EPS (Diluted) | -7.01 | -7.12 | 11.64 | -6.33 | — | — | — | — | — | |
| EBITDA | -417 | -409 | 724 | -345 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | 2.82 | — | — | — | — | — | — | |
| Price To Sales Ratio | 17.85 | 29.24 | 52.03 | 46.19 | — | — | — | — | — | |
| Gross Margin | 87.88 | 79.63 | 88.89 | 62.96 | — | — | — | — | — | |
| Operating Margin | -464.65 | -874.07 | -1,183.33 | -1,448.15 | — | — | — | — | — | |
| Net Margin | -415.15 | -764.81 | 1,872.22 | -1,303.70 | — | — | — | — | — | |
| Shares Outstanding | 59 | 58 | 57 | 56 | — | — | — | — | — | |
| Market Capitalization | 1,767 | 1,579 | 1,873 | 1,247 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
Unlock full historical data
See years of past statements with Premium.
Insider Trading Volume
Insider Trading
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Gheuens Sarah | Chief Medical Officer | Oct 26 '26 | Option Exercise | 25.01 | 7,866 | 196,729 | 62,511 | Oct 28 |
| Gheuens Sarah | Chief Medical Officer | Oct 26 '26 | Sale | 37.69 | 7,866 | 296,470 | 54,645 | Oct 28 |
| Gheuens Sarah | Chief Medical Officer | Oct 22 '26 | Sale | 37.52 | 500 | 18,760 | 54,645 | Oct 23 |
| Gheuens Sarah | Chief Medical Officer | Oct 22 '26 | Option Exercise | 25.01 | 500 | 12,505 | 55,145 | Oct 23 |
| Gheuens Sarah | Chief Medical Officer | Oct 21 '26 | Sale | 37.53 | 1,489 | 55,882 | 54,645 | Oct 23 |
| Gheuens Sarah | Chief Medical Officer | Oct 21 '26 | Option Exercise | 25.01 | 1,489 | 37,240 | 56,134 | Oct 23 |
| Gheuens Sarah | Chief Medical Officer | Aug 04 '26 | Sale | 30.48 | 30,000 | 914,400 | 54,645 | Aug 06 |
| Backstrom Jay T. | Director | Jul 08 '26 | Option Exercise | 0.00 | 1,447 | 0 | 2,894 | Jul 10 |
| Gheuens Sarah | Chief Medical Officer | Jul 01 '26 | Option Exercise | 0.00 | 8,375 | 0 | 88,652 | Jul 02 |
| Gheuens Sarah | Chief Medical Officer | Jul 01 '26 | Sale | 37.56 | 4,007 | 150,503 | 84,645 | Jul 02 |
| Ho Maykin | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 19,848 | Jun 23 |
| Owen Adams Catherine | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 10,865 | Jun 23 |
| Scadden David | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 20,419 | Jun 23 |
| Smith Cynthia | Director | Jun 18 '26 | Option Exercise | 0.00 | 2,816 | 0 | 15,230 | Jun 23 |
| Viswanadhan Krishnan | Chief Strategy and Operations | Jun 18 '26 | Option Exercise | 0.00 | 3,000 | 0 | 9,000 | Jun 23 |
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.